{"gao_id": "GAO-22-104266", "published": "2022-05-12T12:00:00Z", "released": "2022-05-12T08:00:00Z", "summary": "To help increase the availability of COVID-19 tests, the Food and Drug Administration didn't object when some labs used certain tests before they were reviewed for emergency use. Some of the unauthorized tests were eventually authorized, some were denied due to performance or data problems, and others were never reviewed by FDA. FDA began phasing out the use of unauthorized tests in November 2021. But...", "title": "COVID-19: FDA Took Steps to Help Make Tests Available; Policy for Future Public Health Emergencies Needed", "topics": ["Medical devices", "Medical products", "pandemics", "Compliance oversight", "Patient care", "Reporting requirements", "Antibodies", "Health care", "Public health emergencies", "Health Care", "Health care providers", "Public health"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-22-104266", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-22-104266-highlights.pdf"}, {"title": "Full Report (52 pages)", "url": "https://www.gao.gov/assets/gao-22-104266.pdf"}, {"title": "Accessible PDF (59 pages)", "url": "https://www.gao.gov/assets/730/720469.pdf"}]}